AlphaQuest’s Acadia Pharmaceuticals ACAD Stock Holding History

AlphaQuest’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,794	Closed	-$769K	–	17
2025 Q4	$769K	Sell	28,794 -3,457	-11%	-$82.6K	0.04%	561
2025 Q3	$688K	Buy	+32,251	New	+$763K	0.05%	601
2025 Q2	–	Sell	-9,208	Closed	-$153K	–	1993
2025 Q1	$153K	Sell	9,208 -4,303	-32%	-$78.2K	0.02%	1113
2024 Q4	$248K	Buy	13,511 +9,991	+284%	+$161K	0.03%	783
2024 Q3	$54.1K	Buy	3,520 +1,047	+42%	+$17.5K	﹤0.01%	1396
2024 Q2	$40.2K	Sell	2,473 -6,745	-73%	-$109K	0.01%	1124
2024 Q1	$170K	Buy	9,218 +7,965	+636%	+$197K	0.03%	687
2023 Q4	$39.2K	Buy	+1,253	New	+$29.9K	0.01%	909

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

AlphaQuest's ACAD Position: Q1 2026 in Review

AlphaQuest sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 28,794 shares — an estimated $769K sold.

AlphaQuest first reported a position in ACAD in Q4 2023 and held it in 8 quarters. The position peaked at $769K in Q4 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

AlphaQuest reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 28,794 Acadia Pharmaceuticals shares in Q1 2026, an estimated $769K.
AlphaQuest first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 8 quarters.
AlphaQuest's Acadia Pharmaceuticals position peaked at $769K in Q4 2025.
343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.